AKT1 and prostate cancer: S-Oleocanthal was nearly without any significant effect on Akt phosphorylation while it appeared to have a little effect on activated ERK levels only at relatively high treatment dose (20 μM) in this prostate cancer model, compared to vehicle-treated cells (Figure 7B).